Related Experiment Video

Updated: Nov 17, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.1K

Targeting KRAS in Colorectal Cancer

Chongkai Wang1, Marwan Fakih2

  • 1Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E Duarte Rd, Duarte, CA, 91010, USA.

Current Oncology Reports
|February 14, 2021
PubMed
Abstract

Insights

Targeting KRAS G12C mutations, common in cancers like NSCLC, shows promise. New KRAS G12C inhibitors demonstrate potent activity in early clinical trials, offering hope for effective cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • KRAS mutations are frequent genomic alterations in human cancers.
  • Despite decades of effort, no KRAS-targeting therapy has been approved.
  • Recent progress involves targeting the KRAS G12C mutation with specific covalent inhibitors.

Purpose of the Study:

  • To review recent breakthroughs in targeting KRAS mutations, particularly KRAS G12C.
  • To highlight the development and efficacy of KRAS G12C specific inhibitors.

Main Methods:

  • Review of preclinical models and early-phase clinical trials.
  • Analysis of data from inhibitors like sotorasib and MRTX849.
  • Examination of KRAS G12C mutation prevalence in various cancers.

Main Results:

  • KRAS G12C mutations are found in 14% of NSCLC and 3% of colorectal cancer.
  • Potent KRAS G12C inhibitors show significant activity in preclinical models.
  • Early clinical trials indicate promising antitumor activity in NSCLC, colorectal cancer, and other solid tumors with KRAS G12C mutations.

Conclusions:

  • Preclinical success in targeting KRAS has translated into clinical benefits.
  • KRAS G12C inhibitors hold potential to transform the management of KRAS-mutated solid tumors.
  • Further research is needed for biomarkers predicting response and overcoming resistance.
Keywords:
Colorectal cancerKRASTargeting therapy

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.4K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.7K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K